ΒιΆΉ΄«Γ½

Meeting Coverage

GICS

Gastrointestinal Cancers Symposium

Liquid Biopsy Has Mixed Performance for Predicting Colon Cancer Outcomes

Adjuvant chemo fails to move needle on DNA clearance, but dynamics predictive of DFS

GiCS over a photo of Moscone Convention Center West in San Francisco, CA

Latest GICS Meeting Coverage

Big PFS Improvement in Highly Mutated CRC With Dual Immunotherapy

Nivolumab/ipilimumab led to improvement in untreated MSI-H/dMMR disease versus chemo

January 22, 2024
Neoadjuvant PD-1 Blockade Boosts pCR Rates in Early Esophageal Cancer

But will the benefit extend to event-free and overall survival?

January 22, 2024
New Standard for Unresectable Hepatocellular Carcinoma?

Adding durvalumab and bevacizumab to transarterial chemoembolization almost doubles PFS

January 21, 2024
Radioligand Gets Big Win in High-Grade GEP Neuroendocrine Tumors

Lutetium dotatate reduces PFS risk by 72% in randomized trial

January 20, 2024
Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer

But how much did investigational tiragolumab contribute to efficacy?

January 19, 2024
Long-Term Data Affirm First-Line Immunotherapy for Advanced Esophageal Cancer

Three times as many patients alive at 5 years with chemo plus pembrolizumab

January 19, 2024
New Standard of Care for Refractory Metastatic Colorectal Cancer

Significant improvement in OS, PFS with addition of bevacizumab to trifluridine/tipiracil

January 23, 2023
'More Is Not Better' in Two First-Line Trials for Biliary Tract Cancer

No survival benefit with three-drug chemo regimen or clear PFS gain with anti-PD-L1/bevacizumab

January 22, 2023
New First-Line Standard for Metastatic Pancreatic Cancer

Liposomal irinotecan regimen boosts outcomes, although expert expressed concern about toxicity

January 22, 2023
Adding Targeted Drug to Chemo Boosts Survival in Gastric/GEJ Cancer

Longest overall survival reported to date with the addition of zolbetuximab to chemotherapy

January 21, 2023
Perioperative Chemo Matches Multimodal Tx for Locally Advanced Esophageal/GEJ Cancer

Nearly identical 3-year survival, questioning the need for radiotherapy before surgery

January 20, 2023
GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer

Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer

January 24, 2022
Adagrasib Promising in KRAS-Mutant GI Cancers

The KRAS G12C inhibitor showed a disease control rate of 100% in small study

January 24, 2022
Survival Bump in Biliary Cancer With Immunotherapy Plus Chemotherapy

Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade

January 23, 2022